Recurrent aphthous stomatitis (RAS) remains a condition whose pathophysiological mechanism partly eludes formal characterization. In clinical practice, we observe that the majority of patients consult late, after years of episodes managed by self-medication, which delays the identification of atypical forms or underlying systemic pathologies.
Etiological assessment of recurrent aphthae: what differential diagnosis requires
Aphthosis that begins in adulthood, without a history of episodes during childhood, should immediately suggest a secondary cause. The reasoning cannot be limited to classical triggering factors (mucosal trauma, stress, acidic foods). A systematic blood test is now recommended as soon as episodes exceed three to four per year or occur suddenly in a patient without a history.
Recommended read : When to use a miter saw?
This assessment includes at least a complete blood count, ferritin, vitamin B12, folate levels, and celiac serology. An isolated iron deficiency, even without frank anemia, is sufficient to maintain a cycle of mucosal ulcerations. Similarly, silent celiac disease sometimes reveals itself solely through oral aphthae, without digestive symptoms.
When aphthae are accompanied by genital ulcerations, uveitis, or skin lesions, the search for Behçet’s disease becomes a priority. The practitioner must also inquire about the presence of chronic abdominal pain suggesting a chronic inflammatory bowel disease (IBD). These associations radically change management, as treatment shifts from symptomatic local therapy to long-term immunomodulatory therapy.
See also : Renovate to Sell: Techniques and Tips
Exploring the issue of recurrent aphthous stomatitis and treatments allows for a better understanding of situations where a simple dental consultation is no longer sufficient and where an internal medicine opinion is necessary.
PFAPA syndrome and periodic febrile aphthae in children
Autoinflammatory syndromes remain underdiagnosed at the frontline. PFAPA syndrome (periodic fever, recurrent aphthous stomatitis, pharyngitis, adenopathy) is the most common autoinflammatory cause of recurrent aphthae in children. Regular febrile episodes associated with aphthae should raise suspicion of PFAPA before concluding a simple mucosal fragility.
The presentation is stereotypical: fever episodes occurring with remarkable periodicity (every three to eight weeks), accompanied by oral aphthae, pharyngitis, and cervical adenopathy. Between crises, the child is asymptomatic and their growth remains normal.
The management of PFAPA differs entirely from that of a typical RAS:
- A single-dose corticosteroid at the onset of the febrile episode dramatically shortens the crisis, whereas topical oral corticosteroids have no effect on fever or the overall duration of the episode.
- Tonsillectomy is discussed in cases of high recurrence, with favorable results reported in the pediatric literature, although the mechanism remains debated.
- Long-term colchicine may be considered in resistant forms, after specialized pediatric immunology consultation.
We recommend not trivializing recurrent aphthae in a child with regular febrile episodes. Referral to a pediatrician trained in autoinflammatory diseases avoids years of diagnostic wandering.
Treatments for severe RAS: beyond topical corticosteroids
The majority of minor forms of RAS respond to glucocorticoids applied locally (triamcinolone, betamethasone) and antiseptic mouthwashes. Topical treatment remains the first line for minor Mikulicz aphthosis, with satisfactory efficacy on pain and the duration of lesions.
Major forms, on the other hand, pose a real therapeutic problem. Giant aphthae (greater than one centimeter), multiple herpetiform forms, or subintrant episodes that prevent feeding require escalation.
Systemic molecules in refractory aphthosis
Oral colchicine often represents the first systemic step. Its efficacy relies on the inhibition of neutrophil chemotaxis, which reduces the inflammatory component of ulcerations. Digestive tolerance sometimes limits its prolonged use.
Thalidomide, despite its toxicity profile (peripheral neuropathy, strict teratogenicity), still has a place in refractory major aphthosis monitored in specialized oral medicine centers. Its prescription is reserved for disabling forms after failure of other lines.
Recent case data and small series suggest an interest in anti-TNF biotherapies (infliximab, adalimumab) and anti-IL-1 in severe idiopathic aphthosis or associated with Behçet’s disease. These treatments fall under a collegial decision in clinical immunology or internal medicine.
Clinical warning signs: when an aphthous ulcer is no longer trivial
An isolated aphthous ulcer, even painful, heals spontaneously within one to two weeks without scarring. Vigilance is required in the presence of specific criteria:
- A mouth ulcer persisting beyond three weeks without a tendency to heal, which necessitates a biopsy to exclude a neoplastic lesion.
- Aphthae accompanied by systemic signs (recurrent fever, arthralgias, skin lesions, ocular involvement) suggesting an inflammatory syndrome or Behçet’s disease.
- A sudden appearance of multiple aphthae in an adult under a new medication, particularly non-steroidal anti-inflammatory drugs, beta-blockers, or certain mTOR inhibitors, which can induce iatrogenic mucosal ulcerations.
- Aphthae associated with weight loss, chronic diarrhea, or marked asthenia, warranting investigation for IBD or celiac disease.
Any mouth ulcer lasting more than three weeks justifies an anatomical pathology examination. This temporal threshold remains the most reliable clinical marker to distinguish a trivial aphthous ulcer from a potentially malignant lesion.
RAS, in its typical form, remains benign. The real clinical challenge lies in the ability to identify patients whose aphthosis masks a systemic pathology or justifies therapeutic escalation. A meticulous inquiry into periodicity, associated signs, and age of onset guides the diagnosis much more effectively than indefinitely renewed blind local treatment.